Skip to main content

Table 3 Normalized absorbed doses and effective doses for [18F]PR04.MZ for all subjects and selected target organs calculated with IDAC-Dose 2.1

From: Whole-body biodistribution and radiation dosimetry of [18F]PR04.MZ: a new PET radiotracer for clinical management of patients with movement disorders

 

HC-01 (M)

HC-02 (M)

HC-03 (M)

HC-04 (F)

HC-05 (F)

HC-06 (F)

Mean

StDev

CoV (%)

Organ

Normalised absorbed dose (mGy/MBq)

Adrenals

1.43E−02

1.51E−02

1.40E−02

1.94E−02

1.84E−02

1.72E−02

1.64E−02

2.26E−03

13.8

Brain

1.18E−02

1.08E−02

9.72E−03

1.05E−02

1.14E−02

1.09E−02

1.09E−02

7.22E−04

6.7

Breasts

6.71E−03

7.39E−03

6.83E−03

8.48E−03

8.74E−03

9.12E−03

7.88E−03

1.03E−03

13.1

Colon

1.69E−02

1.87E−02

1.56E−02

1.95E−02

1.73E−02

1.67E−02

1.75E−02

1.42E−03

8.1

Cortical bone surface

2.40E−02

2.42E−02

2.59E−02

2.81E−02

2.51E−02

3.04E−02

2.63E−02

2.50E−03

9.5

Eye lenses

5.58E−03

6.18E−03

5.91E−03

7.03E−03

7.12E−03

7.81E−03

6.61E−03

8.50E−04

12.9

Gallbladder wall

3.30E−02

3.65E−02

3.47E−02

3.83E−02

3.01E−02

2.04E−02a

3.22E−02

6.42E−03

20.0

Heart wall

1.16E−02

1.15E−02

1.08E−02

1.23E−02

1.12E−02

1.18E−02

1.15E−02

5.13E−04

4.4

Kidneys

2.12E−02

2.22E−02

1.98E−02

2.25E−02

2.25E−02

2.23E−02

2.18E−02

1.07E−03

4.9

Left colon wall

1.83E−02

1.99E−02

1.60E−02

2.16E−02

1.87E−02

1.83E−02

1.88E−02

1.87E−03

9.9

Liver

2.18E−02

2.23E−02

2.16E−02

2.48E−02

2.42E−02

2.01E−02

2.25E−02

1.75E−03

7.8

Lungs

1.50E−02

1.32E−02

1.37E−02

1.50E−02

1.58E−02

1.74E−02

1.50E−02

1.51E−03

10.0

Muscle

7.25E−03

8.40E−03

7.87E−03

1.01E−02

1.02E−02

1.08E−02

9.10E−03

1.45E−03

15.9

Oesophagus wall

1.10E−02

1.15E−02

1.10E−02

1.25E−02

1.25E−02

1.32E−02

1.20E−02

9.14E−04

7.6

Ovaries

0.00E + 00

0.00E + 00

0.00E + 00

1.56E−02

1.58E−02

1.43E−02

1.52E−02

8.14E−04

5.3

Pancreas

2.59E−02

1.78E−02

1.76E−02

2.16E−02

1.91E−02

1.74E−02

1.99E−02

3.33E−03

16.7

Pituitary gland

9.50E−03

9.72E−03

9.09E−03

1.24E−02

1.24E−02

1.35E−02

1.11E−02

1.88E−03

16.9

Prostate

1.41E−02

1.69E−02

1.62E−02

0.00E + 00

0.00E + 00

0.00E + 00

1.57E−02

1.46E−03

9.3

Rectosigmoid colon wall

1.08E−02

1.28E−02

1.22E−02

1.44E−02

1.45E−02

1.27E−02

1.29E−02

1.40E−03

10.8

Red marrow

2.57E−02

2.61E−02

2.46E−02

2.69E−02

2.72E−02

2.86E−02

2.65E−02

1.38E−03

5.2

Right colon wall

1.84E−02

2.05E−02

1.70E−02

1.99E−02

1.74E−02

1.72E−02

1.84E−02

1.49E−03

8.1

SI wall

1.11E−02

1.23E−02

1.10E−02

1.51E−02

1.43E−02

1.34E−02

1.29E−02

1.69E−03

13.1

Skin

5.08E−03

5.95E−03

5.53E−03

6.88E−03

7.05E−03

7.44E−03

6.32E−03

9.38E−04

14.8

Spleen

1.17E−02

1.15E−02

1.30E−02

1.17E−02

1.08E−02

1.29E−02

1.19E−02

8.55E−04

7.2

Stomach wall

2.45E−02

1.80E−02

1.45E−02

2.26E−02

1.62E−02

1.26E−02

1.81E−02

4.65E−03

25.7

Testes

5.88E−03

7.22E−03

6.63E−03

0.00E + 00

0.00E + 00

0.00E + 00

6.58E−03

6.72E−04

10.2

Thymus

9.25E−03

9.89E−03

9.47E−03

1.11E−02

1.14E−02

1.23E−02

1.06E−02

1.21E−03

11.5

Thyroid

7.81E−03

8.64E−03

8.21E−03

9.66E−03

9.94E−03

1.08E−02

9.18E−03

1.14E−03

12.5

Ureters

1.28E−02

1.45E−02

1.33E−02

1.78E−02

1.72E−02

1.66E−02

1.54E−02

2.12E−03

13.8

Urinary bladder wall

2.44E−02

2.95E−02

2.89E−02

3.07E−02

3.04E−02

1.92E−02

2.72E−02

4.53E−03

16.7

Uterus/Cervix

0.00E + 00

0.00E + 00

0.00E + 00

1.91E−02

1.92E−02

1.54E−02

1.79E−02

2.17E−03

12.1

ICRP Standard

Normalised effective dose (mSv/MBq)

ED ICRP 60

1.75E−02

1.73E−02

1.61E−02

1.65E−02

1.54E−02

1.47E−02

1.63E−02

1.08E−03

6.7

ED ICRP 103

1.59E−02

1.60E−02

1.47E−02

1.91E−02

1.75E−02

1.64E−02

1.66E−02

1.52E−03

9.2

  1. aSubject underwent cholecystectomy prior to inclusion